Russia completes early trials of second potential Covid vaccine
09 Sept 2020
On Tuesday Siberia's Vector virology institute completed early-stage human trials, known as Phase II, of a second potential Russian vaccine against Covid-19 , cited by the Interfax news agency as saying.
In August Russia registered its first vaccine candidate, developed by Moscow's Gamaleya Institute.
Interfax cited watchdog Rospotrebnadzor as saying on July 27 Human trials of the second potential Covid-19 vaccine was begun and involved a group of 100 volunteers.
Interfax quoted in a statement ,"Today the final group of 20 volunteers was released from the hospital." It was further said, "All 100 volunteers were vaccinated with two doses and have completed a 23-day monitoring period in hospital. The volunteers are feeling good."
The vaccine is the first in the world to be authorised for general use. Without phase-3 trials Russian government approved it on August 11.